These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
519 related articles for article (PubMed ID: 32289441)
1. Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies. Szöőr Á; Tóth G; Zsebik B; Szabó V; Eshhar Z; Abken H; Vereb G Cancer Lett; 2020 Aug; 484():1-8. PubMed ID: 32289441 [TBL] [Abstract][Full Text] [Related]
2. A Small Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts. Tóth G; Szöllősi J; Abken H; Vereb G; Szöőr Á Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32033208 [TBL] [Abstract][Full Text] [Related]
3. Construction and evaluation of a novel humanized HER2-specific chimeric receptor. Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843 [TBL] [Abstract][Full Text] [Related]
4. [Specific cytotoxicity of a novel HER2-based chimeric antigen receptor modified T lymphocytes against HER2-positive tumor cells]. Tang HJ; Liu YQ; Bian XC; Feng HL; Gu B; Sun H; Zuo CX; Zhou FY; Liu J Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):714-720. PubMed ID: 29050075 [No Abstract] [Full Text] [Related]
5. Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC. Nagy L; Mezősi-Csaplár M; Rebenku I; Vereb G; Szöőr Á Front Immunol; 2024; 15():1365172. PubMed ID: 38562932 [TBL] [Abstract][Full Text] [Related]
6. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2 Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641 [No Abstract] [Full Text] [Related]
7. In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. Clémenceau B; Valsesia-Wittmann S; Jallas AC; Vivien R; Rousseau R; Marabelle A; Caux C; Vié H J Immunol Res; 2015; 2015():482089. PubMed ID: 26665156 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of the antitumor effect of HER2-directed CAR-T cells through blocking epithelial-mesenchymal transition in tumor cells. Zhang PF; Huang Y; Liang X; Li D; Jiang L; Yang X; Zhu M; Gou HF; Gong YL; Wei YQ; Li Q; Wang W FASEB J; 2020 Aug; 34(8):11185-11199. PubMed ID: 32645243 [TBL] [Abstract][Full Text] [Related]
9. Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting. Eitler J; Wotschel N; Miller N; Boissel L; Klingemann HG; Wels W; Tonn T J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468562 [TBL] [Abstract][Full Text] [Related]
10. HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice. Forsberg EMV; Lindberg MF; Jespersen H; Alsén S; Bagge RO; Donia M; Svane IM; Nilsson O; Ny L; Nilsson LM; Nilsson JA Cancer Res; 2019 Mar; 79(5):899-904. PubMed ID: 30622115 [TBL] [Abstract][Full Text] [Related]
11. Development of the CK-MB-1 trastuzumab-resistant HER2-positive breast cancer cell line and xenograft animal models. Chung WP; Huang WL; Liao WA; Huang WL; Liu YY; Su WC Cancer Med; 2021 Apr; 10(7):2370-2379. PubMed ID: 33665980 [TBL] [Abstract][Full Text] [Related]
12. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells. Gardaneh M; Shojaei S; Kaviani A; Behnam B Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540 [TBL] [Abstract][Full Text] [Related]
13. Development of chimeric antigen receptor-modified T cells for the treatment of esophageal cancer. Yu F; Wang X; Shi H; Jiang M; Xu J; Sun M; Xu Q; Addai FP; Shi H; Gu J; Zhou Y; Liu L Tumori; 2021 Aug; 107(4):341-352. PubMed ID: 32988314 [TBL] [Abstract][Full Text] [Related]
14. ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma. Merker M; Wagner J; Kreyenberg H; Heim C; Moser LM; Wels WS; Bonig H; Ivics Z; Ullrich E; Klingebiel T; Bader P; Rettinger E Front Immunol; 2020; 11():581468. PubMed ID: 33193388 [TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of a human CD47/HER2 bispecific antibody for Trastuzumab-resistant breast cancer immunotherapy. Zhang B; Shi J; Shi X; Xu X; Gao L; Li S; Liu M; Gao M; Jin S; Zhou J; Fan D; Wang F; Ji Z; Bian Z; Song Y; Tian W; Zheng Y; Xu L; Li W Drug Resist Updat; 2024 May; 74():101068. PubMed ID: 38402670 [TBL] [Abstract][Full Text] [Related]
16. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840 [TBL] [Abstract][Full Text] [Related]
17. Switchable CAR-T Cells Outperformed Traditional Antibody-Redirected Therapeutics Targeting Breast Cancers. Cao YJ; Wang X; Wang Z; Zhao L; Li S; Zhang Z; Wei X; Yun H; Choi SH; Liu Z; Zhao L; Kazane SA ACS Synth Biol; 2021 May; 10(5):1176-1183. PubMed ID: 33856201 [TBL] [Abstract][Full Text] [Related]
18. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice. Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001 [TBL] [Abstract][Full Text] [Related]
19. A Novel Siglec-4 Derived Spacer Improves the Functionality of CAR T Cells Against Membrane-Proximal Epitopes. Schäfer D; Henze J; Pfeifer R; Schleicher A; Brauner J; Mockel-Tenbrinck N; Barth C; Gudert D; Al Rawashdeh W; Johnston ICD; Hardt O Front Immunol; 2020; 11():1704. PubMed ID: 32849600 [TBL] [Abstract][Full Text] [Related]
20. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer. Wu G; Li L; Qiu Y; Sun W; Ren T; Lv Y; Liu M; Wang X; Tao H; Zhao L; Cao J; He L; Li H; Gu H Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1625-1639. PubMed ID: 34586349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]